Pain News and Research RSS Feed - Pain News and Research

Plaque can be used to predict, identify and treat diseases, say researchers

Plaque can be used to predict, identify and treat diseases, say researchers

Scraped from the gums, teeth and tongue in the form of plaque, the researchers behind Canada's first plaque bank are betting that the bacterial content of plaque will open up a new frontier of medicine. [More]
Study shows epilepsy drug can protect vision of MS patients

Study shows epilepsy drug can protect vision of MS patients

A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
ASA QCDR adds new quality reporting measures

ASA QCDR adds new quality reporting measures

Physician anesthesiologists can now choose from 36 reporting measures when participating in the ASA QCDR, the American Society of Anesthesiologists Qualified Clinical Data Registry. [More]
Inflammation plays causal role in neurologic changes associated with Lyme disease

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology. [More]
Robert B. Kiningham receives Founders' Award at 2015 AMSSM Annual Meeting

Robert B. Kiningham receives Founders' Award at 2015 AMSSM Annual Meeting

Robert B. Kiningham, MD, was awarded the Founders' Award at the 24th American Medical Society for Sports Medicine Annual Meeting in Hollywood, Fla. The award is bestowed when AMSSM leadership determines that a member exemplifies the best that a sports medicine physician can be and do. [More]
RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx joint venture retains Ora to carry out RGN-259/GBT201 clinical trials in U.S.

RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year. [More]
Medtronic plans to develop stent graft system for treatment of thoracoabdominal aortic aneurysms

Medtronic plans to develop stent graft system for treatment of thoracoabdominal aortic aneurysms

The global leader in medical technology for endovascular aortic repair (EVAR), Medtronic plc today announced that it plans to develop a stent graft system for less invasive treatment of thoracoabdominal aortic aneurysms under an exclusive patent license agreement with South Dakota-based Sanford Health. [More]
Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Two UC Davis researchers awarded grant to help improve surveillance for patients with small lung nodules

Two UC Davis researchers will help run a major national study to improve surveillance practices for patients with small lung nodules identified on CT imaging and extremely low risk for lung cancer. [More]
Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Oxycodone-related deaths drop 25% after implementation of Prescription Drug Monitoring Program

Oxycodone-related deaths dropped 25 percent after Florida implemented its Prescription Drug Monitoring Program in late 2011 as part of its response to the state's prescription drug abuse epidemic, according to a team of UF Health researchers. The drop in fatalities could stem from the number of health care providers who used the program's database to monitor controlled substance prescriptions. [More]
UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

UH Seidman Cancer Center uses SpaceOAR System to perform first-ever prostate cancer treatment

The radiation oncology team at UH Seidman Cancer Center at UH Geauga Medical Center performed the first-ever prostate cancer treatment on April 3 using a newly approved device. The device, called SpaceOAR System, enhances the efficacy of radiation treatment by protecting organs surrounding the prostate. The device, a temporary injectable gel, received FDA clearance on April 1. [More]
Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

Board-certified physiatrist Brian Fellechner joins St. Luke’s University Health Network

St. Luke’s University Health Network is pleased to welcome board-certified physiatrist Brian Fellechner, DO, to its medical staff. A graduate of the Philadelphia College of Osteopathic Medicine, Dr. Fellechner completed his residency in physical medicine and rehabilitation at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School in Newark, New Jersey where he served as chief resident at the Kessler Institute for Rehabilitation. [More]
Johns Hopkins researchers develop LevelCheck software to help improve surgical safety

Johns Hopkins researchers develop LevelCheck software to help improve surgical safety

Because the spine is made up of repeating elements that look alike, surgeons can mistakenly operate on the wrong vertebra. To avoid this, Johns Hopkins researchers have developed a software program that works seamlessly with currently available procedures to assist a surgeon’s determination of which vertebra is which. Results from its first clinical evaluation show that the LevelCheck software achieves 100 percent accuracy in just 26 seconds. [More]
New data support use of Exalenz Bioscience's BreathID test for diagnosing H. pylori infection

New data support use of Exalenz Bioscience's BreathID test for diagnosing H. pylori infection

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced new published data supporting the use of the Company's point-of-care BreathID urea breath test for diagnosing Helicobacter pylori infection (H. pylori) in the emergency department (ED) setting. [More]
ACA calls for 'conservative care first' approach to low-back pain

ACA calls for 'conservative care first' approach to low-back pain

The American Chiropractic Association, in response to recent research calling into question the efficacy of acetaminophen in the management of spinal pain, strongly encourages patients and healthcare providers to consider the benefits of a conservative approach to back pain. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
Mindfulness meditation can reduce pain, anxiety in healthy individuals

Mindfulness meditation can reduce pain, anxiety in healthy individuals

When Rebecca Erwin was a varsity rower at the University of North Carolina, the coach had the team's members take a yoga and meditation class. [More]
Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China. [More]
Early and guideline adherent physical therapy reduces costs, resources in LBP patients

Early and guideline adherent physical therapy reduces costs, resources in LBP patients

A study in the scientific journal BMC Health Services Research shows that early and guideline adherent physical therapy following an initial episode of acute, nonspecific low back pain (LBP) resulted in substantially lower costs and reduced use of health care resources over a 2-year period. [More]
Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%. [More]
Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences announced today the launch of SPHERUSOL (Coccidioides immitis Spherule-Derived Skin Test Antigen), a skin test that provides valuable data to physicians managing Valley Fever infections. SPHERUSOL has been approved by the U.S. Food and Drug Administration as the only skin test to detect an immune response to the fungus called Coccidioides, or "cocci," in patients with history of the disease. [More]
Advertisement
Advertisement